HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $270

HC Wainwright & Co. analyst Andrew S. Fein has maintained a Buy rating on Palvella Therapeutics (NASDAQ: PVLA) and raised the price target from $255 to $270.